Observational studyScientific reports2025
Apolipoprotein E-ε4 allele is associated with perihematomal brain edema and poor outcomes in patients with intracerebral hemorrhage.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05687201 (Effect of Apolipoprotein E4 on Perihematomal Edema and Short-term Prognosis in Patients With Intracerebral Hemorrhage), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Apolipoprotein E4 on Perihematomal Edema and Short-term Prognosis in Patients With Intracerebral Hemorrhage
Who cites it
2 citing papers in PubMed.
- Effect of APOE ε4 Gene on Perihematomal Edema in Intracerebral Hemorrhage: A Prospective Study.Neurocritical care · 2025Article
- Effect of early stepwise controlled decompression combined with mild hypothermia therapy on efficacy, cerebral edema volume, and serum biochemical indices in patients with severe hypertensive intracerebral hemorrhage.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Intracerebral hemorrhage (ICH) poses significant disability and mortality risks and perihematomal edema (PHE) plays a crucial role in ICH prognosis. The ApoE-ε4 allele has been implicated in exacerbating PHE and influencing neurological recovery post-ICH, yet, this specific association has not been explored much. This study aimed to investigate the correlation between ApoE-ε4 allele, PHE, and clinical prognosis in patients with ICH. We conducted a prospective observational cohort study at the Affiliated Hospital of Guizhou Medical University from January 2020 to December 2023. We enrolled patients with supratentorial ICH patients and analyzed ApoE gene alleles, clinical baseline data, blood biochemical indices, and imaging findings. We considered ApoE-ε4 carrier status as an exposure variable and compared PHE volumes between ApoE-ε3 (ε3/ε3) and ApoE-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) carriers. We also compared clinical and imaging characteristics between the good prognosis group (modified Rankin score 0-3) and the poor prognosis group (modified Rankin score 4-6). Finally, we examined the association between ApoEε4 and PHE volume and poor prognosis at discharge. Among 153 patients, 63 (41%) carried ApoE-ε4. ApoE-ε4 carriers had significantly higher PHE volumes at 24 h and on days 5-7 compared to ApoE-ε3 carriers. The poor prognosis group had a higher proportion of ApoE-ε4 carriers (53.9% vs. 28.6%, p = 0.001) and increased PHE volumes. ApoE-ε4 (OR 2.438, p = 0.02) and PHE (OR 1.048, p = 0.015) were independent predictors of poor prognosis. The area under the curve for ApoE-ε4 was 0.627, and for PHE volume, it was 0.698. The ICH patients carrying the ApoE-ε4 allele show severe PHE and poorer outcomes. Carrying ApoE-ε4 gene is an independent predictor for poor outcomes in patients with ICH.Trial registration: ClinicalTrials.gov, NCT05687201. Registered June 1, 2023, Effect of Apolipoprotein E on the Prognosis of Patients with Intracerebral Hemorrhage-Full Text View-ClinicalTrials.gov "prospective registered".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.